These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Structures of the Escherichia coli ribosome with antibiotics bound near the peptidyl transferase center explain spectra of drug action. Dunkle JA; Xiong L; Mankin AS; Cate JH Proc Natl Acad Sci U S A; 2010 Oct; 107(40):17152-7. PubMed ID: 20876128 [TBL] [Abstract][Full Text] [Related]
5. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Hansen LH; Mauvais P; Douthwaite S Mol Microbiol; 1999 Jan; 31(2):623-31. PubMed ID: 10027978 [TBL] [Abstract][Full Text] [Related]
6. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. Kosowska K; Credito K; Pankuch GA; Hoellman D; Lin G; Clark C; Dewasse B; McGhee P; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 2004 Nov; 48(11):4113-9. PubMed ID: 15504829 [TBL] [Abstract][Full Text] [Related]
7. The emerging new generation of antibiotic: ketolides. Zhong P; Shortridge V Curr Drug Targets Infect Disord; 2001 Aug; 1(2):125-31. PubMed ID: 12455409 [TBL] [Abstract][Full Text] [Related]
8. Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA. Garza-Ramos G; Xiong L; Zhong P; Mankin A J Bacteriol; 2001 Dec; 183(23):6898-907. PubMed ID: 11698379 [TBL] [Abstract][Full Text] [Related]
9. A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre. Xiong L; Shah S; Mauvais P; Mankin AS Mol Microbiol; 1999 Jan; 31(2):633-9. PubMed ID: 10027979 [TBL] [Abstract][Full Text] [Related]
10. Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Tu D; Blaha G; Moore PB; Steitz TA Cell; 2005 Apr; 121(2):257-70. PubMed ID: 15851032 [TBL] [Abstract][Full Text] [Related]
11. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Shortridge VD; Zhong P; Cao Z; Beyer JM; Almer LS; Ramer NC; Doktor SZ; Flamm RK Antimicrob Agents Chemother; 2002 Mar; 46(3):783-6. PubMed ID: 11850262 [TBL] [Abstract][Full Text] [Related]
12. Binding site of the bridged macrolides in the Escherichia coli ribosome. Xiong L; Korkhin Y; Mankin AS Antimicrob Agents Chemother; 2005 Jan; 49(1):281-8. PubMed ID: 15616307 [TBL] [Abstract][Full Text] [Related]
13. Crystal structure of the synergistic antibiotic pair, lankamycin and lankacidin, in complex with the large ribosomal subunit. Belousoff MJ; Shapira T; Bashan A; Zimmerman E; Rozenberg H; Arakawa K; Kinashi H; Yonath A Proc Natl Acad Sci U S A; 2011 Feb; 108(7):2717-22. PubMed ID: 21282615 [TBL] [Abstract][Full Text] [Related]
14. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Llano-Sotelo B; Dunkle J; Klepacki D; Zhang W; Fernandes P; Cate JH; Mankin AS Antimicrob Agents Chemother; 2010 Dec; 54(12):4961-70. PubMed ID: 20855725 [TBL] [Abstract][Full Text] [Related]
15. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. Matic V; Kosowska K; Bozdogan B; Kelly LM; Smith K; Ednie LM; Lin G; Credito KL; Clark CL; McGhee P; Pankuch GA; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 2004 Nov; 48(11):4103-12. PubMed ID: 15504828 [TBL] [Abstract][Full Text] [Related]
16. Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. Douthwaite S; Champney WS J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():1-8. PubMed ID: 11566971 [TBL] [Abstract][Full Text] [Related]
17. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Douthwaite S; Hansen LH; Mauvais P Mol Microbiol; 2000 Apr; 36(1):183-93. PubMed ID: 10760175 [TBL] [Abstract][Full Text] [Related]
18. Ketolides: the future of the macrolides? Nilius AM; Ma Z Curr Opin Pharmacol; 2002 Oct; 2(5):493-500. PubMed ID: 12324249 [TBL] [Abstract][Full Text] [Related]
19. Emergence of a 23S rRNA mutation in Mycoplasma hominis associated with a loss of the intrinsic resistance to erythromycin and azithromycin. Pereyre S; Renaudin H; Charron A; Bébéar C; Bébéar CM J Antimicrob Chemother; 2006 Apr; 57(4):753-6. PubMed ID: 16464889 [TBL] [Abstract][Full Text] [Related]
20. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae. Zhanel GG; Hisanaga T; Nichol K; Wierzbowski A; Hoban DJ Expert Opin Emerg Drugs; 2003 Nov; 8(2):297-321. PubMed ID: 14661991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]